12:00 AM
Feb 25, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Sofosbuvir: Phase III data

Top-line data from the double-blind, international Phase III FUSION trial in 201 treatment-experienced patients with chronic HCV genotype 2 or 3 infection who failed prior interferon-based therapy showed that once-daily 400 mg sofosbuvir plus ribavirin given for 12 or 16 weeks each met the primary endpoint of improving SVR12 rate vs. a predefined historic control SVR12 rate (50% and 73%, respectively, vs. 25%, p<0.001 for both). Overall, 63% of patients had HCV genotype 3 infection. In the 12-week arm, SVR12 rates...

Read the full 385 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >